Stockscreener 앱 받기
1.05
1.94%
0.02
전일 마감가:
$1.03
열려 있는:
$1.02
하루 거래량:
1.46M
Relative Volume:
0.28
시가총액:
$306.92M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.8889
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+5.17%
1개월 성능:
-1.87%
6개월 성능:
+46.26%
1년 성능:
-19.85%
1일 변동 폭
$1.02
$1.055
1주일 범위
$0.96
$1.0693
52주 변동 폭
$0.515
$1.40
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.05 | 321.67M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Will Ocugen Inc. benefit from rising consumer demand2025 Geopolitical Influence & Free Accurate Trade Setup Notifications - thegnnews.com
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Will Ocugen Inc. Benefit From Broader Market BounceJuly 2025 Review & High Win Rate Trade Alerts - newsyoung.net
Is Ocugen Inc. part of any ETFMarket Weekly Review & Safe Entry Momentum Stock Tips - newsimpact.co.kr
Ocugen reports EMA positive advice for acceptability of OCU410ST - MSN
Can Ocugen Inc. benefit from deglobalization2025 Top Gainers & Verified Swing Trading Watchlists - sundaytimes.kr
EMA's CHMP Gives Ocugen the Green Light to Submit MAA for OCU410ST Based on GARDian3 Trial - CGTLive®
How to contact the Daily Bulletin - FinancialContent
Ocugen's Strategic Advancements and Financial Positioning Support Buy Rating - AInvest
Ocugen’s Strategic Advancements and Financial Positioning Underpin Buy Rating - TipRanks
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen
Acuity Inc. shares rise 1.01% premarket after Ocugen, Inc. receives positive scientific advice. - AInvest
Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy - MarketScreener
Ocugen, Inc. Announces Positive Scientific Advice from the Europ - GuruFocus
Ocugen gets EMA backing for single trial of Stargardt disease therapy - Investing.com Australia
Ocugen, Inc. Announces Positive Scientific Advice from the - GlobeNewswire
Ocugen's Stargardt Disease Treatment Gets Fast-Track to EU Approval with Single Trial Plan - Stock Titan
Janus Henderson Group Plc shares rise 1.98% after-hours following $20 million investment in Ocugen, Inc. - AInvest
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen raises $20 million in direct offering to Janus Henderson - Investing.com
Ocugen raises $20 million in direct offering to Janus Henderson By Investing.com - Investing.com South Africa
Ocugen Secures $20 Million in Registered Direct Offering, Extending Cash Runway into 2026 - AInvest
Ocugen secures crucial $20M funding from Janus Henderson, could unlock additional $30M from warrants - Stock Titan
Ocugen Announces $20M Securities Purchase Agreement to Bolster Gene Therapy Programs - AInvest
Ocugen Announces $20M Securities Purchase Agreement - TipRanks
Ocugen Announces $20 Million Registered Direct Offering of Common Stock and Warrants. - AInvest
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):